Nuclear Medicine Core

核医学核心

基本信息

批准号：
8546162
负责人：
Joseph G Rajendran
金额：
$ 58.97万
依托单位：
FRED HUTCHINSON CANCER RESEARCH CENTER
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

项目摘要

Core B is the Nuclear Medicine Core and is responsible for the following: 1. Preparation of trace-labeled [131]l-BC8 Ab, [111]In labeled DOTA-BC8 Ab, [86]Y labeled DOTA-BC8 Ab, [111]In labeled DOTA-1F5 Ab, and [111]In labeled DOTA-biotin for evaluation of biodistributions in patients with AML, ALL, MDS, and NHL. (Projects 1, 2 and 3) 2. Performance of serial quantitative gamma camera imaging a. Performance of planar imaging in multiple projections in leukemia and lymphoma patients infused with trace-labeled [131]l-anti-CD45 (BCS), [111]In-DOTA BC8, or [111]In labeled DOTA-anti CD20 (1F5) antibodies; or with BC8-streptavidin (BC8-SA) conjugate followed by [111]In labeled DOTA-biotin (Projects 1, 2 and 3) b. Performance of SPECT imaging in one or more body regions for 3D reconstruction of uptake in normal organs and tumor to estimate or normalize uptake for dosimetry evaluation in patients with measurable lymphoma (one SPECT scan per patient performed 24 hours after infusion). (Projects 2 & 3) c. Performance of sequential biodistribution and dosimetry studies comparing: i. [111]In labeled DOTA-anfi-CD45 (BCS) and [111]In labeled DOTA-anti CD20 (1F5) antibodies in patients with NHL (Project 2) ii. [111]In labeled DOTA-anti-CD45 (BCS) and [86]Y labeled DOTA BCS Ab in patients with NHL (Project 2) iii. [111]In labeled DOTA-anfi-CD45 (BCS) Ab vs BCS-SA followed by [111]In labeled DOTA biotin in patients with leukemia and lymphoma. (Project 3) 3, Performance of PET imaging on days 0, 1, 2 and 3 in patients with NHL lymphoma after trace-labeled infusion of [86]Y-DOTA anti-CD 45 (BCS) Ab (Project 2) 4, Quantification of biodistribution and estimate radiation absorbed doses of [131]l-BC8, [111]In DOTA-BC8 Ab, [111]In DOTA-1F5 Ab, and [111]In labeled DOTA biotin for evaluation and treatment of patients with [131]I - or [90]Y-labeled anti-CD 45 (BC8) Ab (Projects 1 and 2) or BC8-SA followed by [90]Y labeled DOTA biotin. (Project 3) 5. Preparation and administration of therapeutic doses of [131]I or [90]Y-DOTA-BC8 antibodies and [90]Y-labeled DOTA biotin for treatment of patients with lymphoma and leukemia, (Projects 1, 2 and 3) 6. Provision of radiation safety monitoring and counseling for patients and staff. (Projects 1, 2, and 3)

核心B是核医学核心，负责以下各种： 1。在标记的dota-bc8 ab中制备痕量标记的[131] L-BC8 AB，[111]，[86]标记为dota-bc8 ab，[111] 标记为DOTA-1F5 AB和[111]在标记的DOTA-Biotin中，用于评估AML患者的生物分布，所有，MD和NHL。（项目1、2和3） 2。串行定量伽马相机成像的性能一个。在白血病和淋巴瘤患者中的多种投影中的平面成像的性能痕量标记的[131] l-anti-cd45（BCS），[111] in-dota bc8或[111]在标记的dota-anti cd20（1f5）抗体中；或与BC8-链霉亲素（BC8-SA）结合在一起，然后在标记的dota-biotin中[111]（项目1、2和3） b。在一个或多个身体区域中进行SPECT成像的性能3D重建在可测量的淋巴瘤（输注24小时后，每名患者进行一项SPECT扫描）。（项目2和3） c。比较顺序生物分布和剂量法研究的性能：我。 [111]在标记的dota-anfi-cd45（bcs）和[111]中，在患者中标记的dota-anti cd20（1f5）抗体中与NHL（项目2） ii。 [111]在标记为DOTA-ANTI-CD45（BCS）和[86] NHL患者的DOTA BCS AB（项目2）中 iii。 [111]在标记的dota-anfi-cd45（BCS）中，AB vs bcs-sa，然后在标记的dota biotin中[111] 白血病和淋巴瘤患者。（项目3） 3，痕量标记后NHL淋巴瘤患者的第0、1、2和3天PET成像的性能输注[86] Y-DOTA抗CD 45（BCS）AB（项目2） 4，生物分布的定量和估计辐射吸收的剂量[131] l-bc8，[111]在dota-bc8 ab中 [111]在DOTA-1F5 AB中，[111]在标记的DOTA生物素中用于评估和治疗[131] I-或[90] y标记的患者抗CD 45（BC8）AB（项目1和2）或BC8-SA，然后是[90] Y标记的Dota Biotin。（项目3） 5。[131] i或[90] y-dota-bc8抗体和[90] y标记的治疗剂量的制备和给药用于治疗淋巴瘤和白血病患者的DOTA生物素（项目1、2和3） 6。为患者和员工提供辐射安全监控和咨询。（项目1、2和3）